Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vincristine + doxorubicin + actinomycin D + ifosfamide
- Development stage
- Phase 4
- Lead developer
- King Faisal Specialist Hospital and Research Centre
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A multi-agent chemotherapy regimen evaluated by the King Faisal Specialist Hospital & Research Center for the treatment of Ewing sarcoma. This combination therapy includes vincristine, doxorubicin (Adriamycin), actinomycin D (dactinomycin), and ifosfamide. The regimen utilizes multiple mechanisms of action to combat tumor growth: vincristine is a vinca alkaloid that inhibits microtubule formation during mitosis; doxorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II; actinomycin D is a cytotoxic antibiotic that intercalates DNA and inhibits RNA synthesis; and ifosfamide acts as a DNA alkylating agent. This pilot study aimed to assess the efficacy and safety of this intensive combination in patients with the Ewing sarcoma family of tumors.
- Other names
- VAI regimenVACA regimenVincristine, Adriamycin, Actinomycin D, IfosfamideVincristine, Actinomycin-D, Ifosfamide
02
Targets
DNATopoisomerase I/II-DNA cleavage complexesTUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on vincristine + doxorubicin + actinomycin D + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vincristine + doxorubicin + actinomycin D + ifosfamide.